Featured Research

from universities, journals, and other organizations

Studies pinpoint key targets for MRSA vaccine

August 17, 2010
University of Chicago Medical Center
Two studies point to a new way to a vaccinate against drug-resistant Staphylococcus aureus -- also known as MRSA -- the leading US cause of skin, soft tissue, bloodstream and lung infections, as well as deaths from infectious disease. One counteracts the bacteria's tools for evading the immune system; the other disrupts the germ's tissue-damaging mechanism. Each approach reduced the microbe's virulence in mice. The combination may protect people from MRSA and provide lasting immunity.

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA -- the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

Related Articles

Each approach dramatically reduced the virulence of staph infections in mice. The combination may protect people from MRSA infections and provide lasting immunity to this virulent and drug-resistant organism, which has become the leading cause of death from infectious disease in the United States.

Since the 1960s, development of a staph vaccine has been a priority for the medical profession--but less so for the pharmaceutical industry, which has veered away from vaccine research. Previous attempts at a MRSA vaccine have failed. In the last decade, however, as staph increased its ability to resist multiple antibiotics and drug-resistant strains came to dominate the community setting, the search for a protective vaccine has moved to center stage.

One of the challenges in creating a vaccine is the ability of this germ to short-circuit the host's defenses. Most bacterial infections trigger an immune counter-attack designed to rid the body of the microbe and prevent subsequent infections. Most vaccines rely on this same strategy. Staph, however, has evolved its own tools to blunt the immune response.

"Staph aureus is the world champion of immune suppression," said the senior author of both studies, Olaf Schneewind, PhD, professor and chair of microbiology at the University of Chicago. This allows the organism to persist long enough to escape the blood stream and settle into various tissues, where it builds a protective capsule, replicates and soon spreads in greater numbers to additional sites.

"Even when the infection can be cleared with antibiotics and surgery, the patient has no immunity," he said. "So these infections often recur."

An effective vaccine requires finding the right targets: proteins key to the disease process and exposed on the cell surface. Schneewind and colleague Dominique Missiakas, PhD, associate professor of microbiology at the University, began by assembling a library of all 23 surface proteins made by staph and created new strains with a mutated version of each protein. So each strain was normal except for one disabled surface protein. When they exposed mice to these mutant microbes, two sets of potential vaccine targets emerged.

One, known as protein A, is a cell-surface molecule than binds to receptors on B cells, the white blood cells that produce antibodies. Protein A is the key to staph's ability to evade immunity. It shields the bacteria by "cross-linking" two receptors on the B cells. This triggers cell death. So mice confronted with a staph infection do not make antibodies against the bacteria.

In the August 17, 2010, issue of the Journal of Experimental Medicine, Schneewind's team tested a way around that obstacle. They found that staph with a mutant version of protein A, unable to short-circuit B cells, did stimulate an immune response. Mice exposed to the "non-toxic" version of protein A were able to mount an effective immune response, killing bacteria, -- including the virulent strain known as USA300, the current source of about 60 percent of staph infections. The vaccine enabled these mice to reduce tissue damage and prevent, or at least delay, death.

"I believe," said Schneewind, "that protein A may be the key to making a staphylococcal vaccine."

The second target was a set of two clotting factors, coagulase and von Willebrand factor binding protein (vWbp), that the bacteria use to assemble protected niches within various tissues where they can replicate.

When the bacteria leave the blood stream, they settle into various organs, such as the kidneys. In this setting, they use these clotting factors to build a protected environment, called an abscess, where they can multiply. After several days, these abscesses rupture, spilling a new load of bacteria into the bloodstream where they can disseminate to uninfected tissues.

Bacteria that lacked functional versions of these two clotting factors were unable to form abscesses or persist in infected tissues. In the August 2010 issue of PLoS Pathogens, Schneewind and colleagues show that by generating antibodies to these two clotting factors and transferring them to infected mice, they could protect those mice from a staph infection.

The also made and tested an anti-coagulase vaccine by injecting purified versions of the clotting factors from a different kind of bacteria (E. coli) into mice and allowing the mice time to produce antibodies. About two weeks later they injected the mice with staph. Even when injected with the USA300, mice vaccinated with both antigens had far fewer abscesses and survived longer.

"The establishment of abscess lesions can be blocked with antibodies specific for coagulases," the authors conclude. "These data further corroborate the concept that Coagulase and vWbp should be considered for staphylococcal vaccine development."

Studies testing the ability of a vaccine combining both approaches are underway.

Both studies were funded by the National Institutes of Health, including the Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases, a program supported the National Institute of Allergy and Infectious Diseases, and by Novartis Vaccines and Diagnostics. Additional authors include Hwan Keun Kim, Alice Cheng, Hye-Young Kim, Molly McAdow, all students at the University of Chicago, and Taeok Bae of the Indiana University School of Medicine-Northwest and an associate member of the Schneewind laboratory.

Story Source:

The above story is based on materials provided by University of Chicago Medical Center. Note: Materials may be edited for content and length.

Journal References:

  1. Hwan Keun Kim, Alice G. Cheng, Hye-Young Kim, Dominique M. Missiakas, Olaf Schneewind. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. Journal of Experimental Medicine, 2010; DOI: 10.1084/jem.20092514
  2. Alice G. Cheng, Molly McAdow, Hwan K. Kim, Taeok Bae, Dominique M. Missiakas, Olaf Schneewind, Ambrose Cheung. Contribution of Coagulases towards Staphylococcus aureus Disease and Protective Immunity. PLoS Pathogens, 2010; 6 (8): e1001036 DOI: 10.1371/journal.ppat.1001036

Cite This Page:

University of Chicago Medical Center. "Studies pinpoint key targets for MRSA vaccine." ScienceDaily. ScienceDaily, 17 August 2010. <www.sciencedaily.com/releases/2010/08/100816095627.htm>.
University of Chicago Medical Center. (2010, August 17). Studies pinpoint key targets for MRSA vaccine. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2010/08/100816095627.htm
University of Chicago Medical Center. "Studies pinpoint key targets for MRSA vaccine." ScienceDaily. www.sciencedaily.com/releases/2010/08/100816095627.htm (accessed November 29, 2014).

Share This

More From ScienceDaily

More Plants & Animals News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
New Dinosaur Species Found in Museum Collection

New Dinosaur Species Found in Museum Collection

Reuters - Innovations Video Online (Nov. 27, 2014) A British palaeontologist has discovered a new species of dinosaur while studying fossils in a Canadian museum. Pentaceratops aquilonius was related to Triceratops and lived at the end of the Cretaceous Period, around 75 million years ago. Jim Drury has more. Video provided by Reuters
Powered by NewsLook.com
Tryptophan Isn't Making You Sleepy On Thanksgiving

Tryptophan Isn't Making You Sleepy On Thanksgiving

Newsy (Nov. 27, 2014) Tryptophan, a chemical found naturally in turkey meat, gets blamed for sleepiness after Thanksgiving meals. But science points to other culprits. Video provided by Newsy
Powered by NewsLook.com
Classic Hollywood Memorabilia Goes Under the Hammer

Classic Hollywood Memorabilia Goes Under the Hammer

Reuters - Entertainment Video Online (Nov. 26, 2014) The iconic piano from "Casablanca" and the Cowardly Lion suit from "The Wizard of Oz" fetch millions at auction. Sara Hemrajani reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories

Plants & Animals

Earth & Climate

Fossils & Ruins

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins